Involving, Empowering, and Training End Users with Disabilities to Fully Participate in the Web Accessibility Directive Objectives First Results from the UPowerWAD Project.

In this paper, we present the first results from the UPowerWAD Project - a project which aims to raise awareness and to empower and train people with disabilities to take active participation in the implementation of the Web Accessibility Directive (WAD). We give an overview of the results on how to capture and categorize feedback from users in the context of web accessibility and present best practices for structuring and reporting web accessibility issues. The results will be discussed focusing on the relevance and implications for further steps in the project.

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.

Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has been evaluated in solid tumors as a single agent or in combination with chemotherapy and radiation. Cervical cancer patients who are refractory or progressive to first-line chemotherapy have a dismal prognosis, and no second- or third-line chemotherapy is considered standard. This pilot trial aimed to evaluate the efficacy and safety of nimotuzumab in 17 patients with pre-treated advanced refractory or progressive cervical cancer. Nimotuzumab was administered weekly at 200 mg/m(2) as single agent for 4 weeks (induction phase), then concurrent with 6 21-day cycles of gemcitabine (800 mg/m(2)) or cisplatin (50 mg/m(2)) for 18 weeks (concurrent phase) and then once every 2 weeks (maintenance phase). Nimotuzumab could be continued beyond disease progression. Seventeen patients were accrued and evaluated for safety and efficacy. The median number of nimotuzumab applications was 20 (5-96). The median number of chemotherapy cycles administered was 6 (1-6). No toxicity occurred during induction and maintenance phases (single agent nimotuzumab). In the concurrent phase, grade 3 toxicity events observed were leucopenia, anemia and diarrhea in 11.7%, 5.8% and 11.7% respectively. No complete or partial responses were observed. The stable disease (SD) rate was 35%. The median PFS and OS rates were 163 days (95% CI, 104 to 222), and 299 days (95% IC, 177 to 421) respectively. Nimotuzumab is well tolerated and may have a role in the treatment of advanced cervical cancer.

Humanismo existencial y medicina / Humanism existence and medicine

Dejando de lado el humanismo trascendental, presentamos una breve revisión del conjunto de conocimientos, logros técnicos y espirituales que conforman el humanismo existencial a través de la magia, la ciencia, la filosofía y la ética. El ser humano a pesar de sus logros fascinantes, se acercan periódicamente a tremendos riesgos y peligros que pueden conducirlo a la extinción no solo de la sociedad humana sino de la vida misma. Si la técnica, asombrosamente sofisticada de hoy, retroalimenta el empobrecimiento de la ética humana, el camino que nos queda por recorrer incluirá el eclipse de la calidad de vida y otros riesgos no imaginados.